Vestcor Inc Bei Gene, Ltd. Transaction History

Vestcor Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$121.11 - $216.05 $128,497 - $229,229	-1,061 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$146.52 - $269.56 $311,208 - $572,545	-2,124 Reduced 66.69%	1,061 $200,000
Q3 2021 Nov 15, 2021	BUY	$249.6 - $403.14 $585,312 - $945,363	2,345 Added 279.17%	3,185 $1.16 Million
Q2 2021 Aug 16, 2021	BUY	$292.75 - $367.01 $245,910 - $308,288	840 New	840 $288,000
Q4 2020 Feb 16, 2021	SELL	$221.31 - $316.61 $225,293 - $322,308	-1,018 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$123.9 - $195.41 $21,682 - $34,196	-175 Reduced 14.67%	1,018 $192,000
Q1 2020 May 13, 2020	BUY	$121.84 - $173.19 $74,809 - $106,338	614 Added 106.04%	1,193 $147,000
Q4 2019 Feb 12, 2020	BUY	$115.78 - $208.34 $67,036 - $120,628	579 New	579 $96,000

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.6B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Vestcor Inc, based on Form 13F filings with the SEC.

Stay updated on Vestcor Inc with notifications on news.